Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:56:14.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating an update in the clinical anti-tumor activity evaluation of pembrolizumab monotherapy for patients with recurrent ovarian cancer based on objective response rate (ORR) as assessed by the investigator per immune related Response Evaluation Criteria in Solid Tumors (irRECIST). This change reflects a modification in the study's assessment criteria and potential outcomes for participants with recurrent ovarian cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:16.000Z thumbnail image
  7. Check
    26 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as a person's general health condition or prior treatments. This change clarifies the criteria researchers use to select participants for clinical studies.
    Difference
    48%
    Check dated 2024-05-22T21:13:54.000Z thumbnail image
  8. Check
    47 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:32:13.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.